Literature DB >> 16908986

BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease.

Diana-Ines Dominguez1, Dieter Hartmann, Bart De Strooper.   

Abstract

Two enzymatic activities are required to generate the pathogenic beta-amyloid (Abeta) peptide that accumulates in the brain of Alzheimer's disease patients. Both activities are carried out by two unusual aspartyl proteases known as beta- and gamma-secretase. Their therapeutic inhibition appears, therefore, a promising strategy to treat the disease. Transgenic mouse models in which the genes encoding the secretases have been ablated offer an invaluable tool, on the one hand, to gain more insights into the biological function of these proteases and, on the other hand, to predict the consequences that might be associated with enzyme inhibition in vivo. Copyright 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16908986     DOI: 10.1159/000080982

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  7 in total

1.  Presenilins regulate the cellular level of the tumor suppressor PTEN.

Authors:  Han Zhang; Runzhong Liu; Ruishan Wang; Shuigen Hong; Huaxi Xu; Yun-wu Zhang
Journal:  Neurobiol Aging       Date:  2007-01-12       Impact factor: 4.673

2.  The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.

Authors:  Wang-Xia Wang; Bernard W Rajeev; Arnold J Stromberg; Na Ren; Guiliang Tang; Qingwei Huang; Isidore Rigoutsos; Peter T Nelson
Journal:  J Neurosci       Date:  2008-01-30       Impact factor: 6.167

3.  A differential proteomic approach reveals an evolutionary conserved regulation of Nme proteins by Fe65 in C. elegans and mouse.

Authors:  Francesco Napolitano; Fulvio D'Angelo; Marida Bimonte; Valeria Perrina; Chiara D'Ambrosio; Andrea Scaloni; Tommaso Russo; Nicola Zambrano
Journal:  Neurochem Res       Date:  2008-04-10       Impact factor: 3.996

4.  Biomarkers in Alzheimer's disease: a review.

Authors:  Meena Chintamaneni; Manju Bhaskar
Journal:  ISRN Pharmacol       Date:  2012-06-28

Review 5.  Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.

Authors:  L O Santos; A S Garcia-Gomes; M Catanho; C L Sodre; A L S Santos; M H Branquinha; C M d'Avila-Levy
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

7.  Recombinant pre-miR-29b for Alzheimer´s disease therapeutics.

Authors:  Patrícia A Pereira; Joana F Tomás; João A Queiroz; Ana R Figueiras; Fani Sousa
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.